We have been reporting on board’s gender diversity since 2009, and while progress has undoubtedly been made, the road ahead is still long. Linda-Eling Lee from MSCI’s Sustainability Institute tells us why we started compiling this report in the first place, and how it has managed to remain relevant in 2024. Then, our colleague Christina Milhomem tells us what the numbers say- what has or hasn’t changed, which regulations are coming our way- and why investors should think of diversity as an indicator of management oversight.

Biodiversity is everywhere from food production to pharmaceutical drugs, so the biodiversity crisis puts both society and the global economy at risk. And while it is like the climate crisis in its cause, there are complexities and measurement difficulties that make the biodiversity crisis a distinct problem for investors to address compared to the climate crisis. On this episode we sat down with our colleague Arne Klug to understand where this complexity comes from and how can investors go about it when trying to include biodiversity in their investment practices.

The EU’s proposed CSDDD could substantially up the stakes in human-rights law for companies and investors. Our research found that many of those in scope for CSDDD fell short on baseline practices to prevent human rights abuses. 

You trust a retail store to be convenient. You can walk in and get basically anything you need - be it food, clothes, face wash, batteries...whatever. Retail companies have built their brands on that convenience and affordability factor. But would you trust a retail company to be your healthcare provider? Well, they are betting on that - Amazon, Walmart, and others are getting into the healthcare game. And in this episode, we discuss what it might look like to have an Amazon employee administer a flu test.

Extreme droughts are putting great pressure on hydro and thermoelectric power producers, which need water to cool thermal power plants. Investors are watching to see how utilities manage water stress.